These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2020088)

  • 1. Inhibition of thromboxane A2 synthetase failed to limit myocardial infarct size in a rabbit ischemia-reperfusion model.
    Tsuchida A; Miura T; Ogawa T; Iwamoto T; Shimamoto K; Iimura O
    Jpn Circ J; 1991 Feb; 55(2):174-83. PubMed ID: 2020088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-type plasminogen activator alone or in combination with thromboxane A2 synthetase inhibitor for ischemic myocardium.
    Ogawa T; Miura T; Tsuchida A; Iwamoto T; Urabe K; Endoh A; Iimura O
    Can J Cardiol; 1990 Oct; 6(8):361-6. PubMed ID: 2125235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a thromboxane synthetase inhibitor, Y-20811, on infarct size, neutrophil accumulation, and arrhythmias after coronary artery occlusion and reperfusion in dogs.
    Sato N; Endo T; Kiuchi K; Hayakawa H
    J Cardiovasc Pharmacol; 1993 Mar; 21(3):353-61. PubMed ID: 7681494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a thromboxane A2 synthetase inhibitor on ventricular fibrillation threshold during coronary artery occlusion and reperfusion.
    Toda I; Nozaki A; Kawakubo K; Murakawa Y; Inoue H; Yoshimoto N; Sugimoto T
    Jpn Heart J; 1990 Jan; 31(1):87-97. PubMed ID: 2335849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
    Vandeplassche G; Hermans C; Somers Y; Van de Werf F; de Clerck F
    J Am Coll Cardiol; 1993 Apr; 21(5):1269-79. PubMed ID: 8459087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart.
    Ito T; Toki Y; Hieda N; Okumura K; Hashimoto H; Ogawa K; Satake T
    Jpn Circ J; 1989 Sep; 53(9):1115-21. PubMed ID: 2513429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of thromboxane A2 synthetase inhibitor, DP-1904 on the action of vasoactive substances in rabbit blood vessel smooth muscle preparations].
    Shimizu K; Kobayashi J; Iwanaga T; Kuratomi Y; Kitamura S
    Nihon Kyobu Shikkan Gakkai Zasshi; 1989 May; 27(5):591-6. PubMed ID: 2615099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of the thromboxane A2/prostaglandin endoperoxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion.
    Grover GJ; Schumacher WA; Simon M; Parham C
    J Cardiovasc Pharmacol; 1988 Dec; 12(6):701-9. PubMed ID: 2467089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial salvage by a novel thromboxane A2 synthetase inhibitor in a canine coronary occlusion-reperfusion model.
    Toki Y; Hieda N; Okumura K; Hashimoto H; Ito T; Ogawa K; Satake T
    Arzneimittelforschung; 1988 Feb; 38(2):224-7. PubMed ID: 3370068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of inotropic dose of dobutamine during reperfusion on myocardial infarct size.
    Ooiwa H; Miura T; Downey JM; Matsuki T; Shizukuda Y; Adachi T; Tsuchida A; Iwamoto T; Ogawa T; Iimura O
    Jpn Circ J; 1989 Dec; 53(12):1511-20. PubMed ID: 2632820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist.
    Nichols WW; Mehta J; Wargovich TJ; Franzini D; Lawson D
    Angiology; 1989 Mar; 40(3):209-21. PubMed ID: 2537051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of infarct size and infiltration of polymorphonuclear leukocytes by a thromboxane synthetase inhibitor. Studies in a rabbit ischemic heart model.
    Ito T; Asai F; Ushiyama S; Matsuda K; Oshima T
    Arzneimittelforschung; 1990 Jan; 40(1):23-7. PubMed ID: 1692704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible role of thromboxane A2 in remote hind limb preconditioning-induced cardioprotection.
    Sharma R; Randhawa PK; Singh N; Jaggi AS
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jan; 389(1):1-9. PubMed ID: 26531833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of coronary circulatory failure and thromboxane A2 release during coronary occlusion and reperfusion by 2-phenylaminoadenosine (CV-1808) in anesthetized dogs.
    Tanabe M; Terashita Z; Nishikawa K; Hirata M
    J Cardiovasc Pharmacol; 1984; 6(3):442-8. PubMed ID: 6202970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of the endothelin ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion.
    McMurdo L; Thiemermann C; Vane JR
    Br J Pharmacol; 1994 May; 112(1):75-80. PubMed ID: 8032665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic modelling of DP-1904, a novel thromboxane synthetase inhibitor in rabbits, based on an indirect response model.
    Zheng NX; Sato H; Adachi I; Horikoshi I
    Eur J Drug Metab Pharmacokinet; 1996; 21(4):285-93. PubMed ID: 9074892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlative alteration of thromboxane A2 with antigen-induced bronchoconstriction and the role of platelets as a source of TXA2 synthesis in guinea pigs: effect of DP-1904, an inhibitor of thromboxane synthetase.
    Takami M; Tsukada W
    Pharmacol Res; 1998 Aug; 38(2):133-9. PubMed ID: 9721601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human superoxide dismutase failed to limit the size of myocardial infarct after 20-, 30-, or 60-minute ischemia and 72-hour reperfusion in the rabbit.
    Miura T; Ogawa S; Ooiwa H; Adachi T; Noto T; Shizukuda Y; Iimura O
    Jpn Circ J; 1989 Jul; 53(7):786-94. PubMed ID: 2810689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.